Drug – bio-affecting and body treating compositions – Antigen – epitope – or other immunospecific immunoeffector – Recombinant virus encoding one or more heterologous proteins...
Patent
1995-04-05
1999-01-26
Stucker, Jeffrey
Drug, bio-affecting and body treating compositions
Antigen, epitope, or other immunospecific immunoeffector
Recombinant virus encoding one or more heterologous proteins...
435236, 4241881, 4242081, 4242321, A61K 3912, A61K 3921, A61K 39275
Patent
active
058635424
ABSTRACT:
Attenuated recombinant viruses containing DNA encoding an immunodeficiency virus and/or CTL antigen, as well as methods and compositions employing the viruses, expression products therefrom, and antibodies generated from the viruses or expression products, are disclosed and claimed. The recombinant viruses can be NYVAC or ALVAC recombinant viruses. The DNA can code for at least one of: HIV1gag(+pro)(IIIB), gp120(MN)(+transmembrane), nef(BRU)CTL, pol(IIIB)CTL, ELDKWA or LDKW epitopes, preferably HIV1gag(+pro)(IIIB), gp120(MN) (+transmembrane), two (2) nef(BRU)CTL and three (3) pol(IIIB)CTL epitopes; or two ELDKWA in gp120 V3 or another region or in gp160. The two (2) nef(BRU)CTL and three (3) pol(IIIB)CTL epitopes are preferably CTL1, CTL2, pol1, pol2 and pol3. The recombinant viruses and gene products therefrom and antibodies generated by the viruses and gene products have several preventive, therapeutic and diagnostic uses. DNA from the recombinant viruses are useful as probes or, for generating PCR primers or for immunization. Also disclosed and claimed are HIV immunogens and modified gp160 and gp120.
REFERENCES:
Tartaglia et al., 1992, AIDS Res. Human Retro. 8(8):14451447.
Cadoz et al., 1992, Lancet 339(8807):1429-1432.
Berman et al., 1990, Nature 345:622-625.
Girard et al., 1991, Proc. Natl. Acad. Sci. USA 88:542-546.
Muster et al., 1993, J. Virol 67(11):6642-6647.
Murphy, F., 1996, "Virus Taxonomy", in Fields Virology, Third Edition, Fields et al., eds., Lippincott-Raven Publishers, Philadelphia, pp. 15-57.
Cox William I.
Paoletti Enzo
Tartaglia James
Frommer William S.
Kowalski Thomas J.
Parkin Jeffrey S.
Stucker Jeffrey
Virogenetics Corporation
LandOfFree
Recombinant attenuated ALVAC canaryopox virus containing heterol does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Recombinant attenuated ALVAC canaryopox virus containing heterol, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Recombinant attenuated ALVAC canaryopox virus containing heterol will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1448157